agilon health (AGL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting is scheduled for June 2, 2026, with voting on director elections, auditor ratification, and executive compensation approval.
The company emphasizes its Total Care Model, focusing on value-based care for seniors, quality outcomes, and operational efficiency.
Leadership transitioned in 2025, with the CEO resigning and the Executive Chairman assuming interim leadership, supported by a strengthened executive team.
The company faced profitability pressures in 2025 but responded with strategic actions to restore financial strength and prioritize margin over membership growth.
Proxy materials are delivered electronically to reduce costs and environmental impact.
Voting matters and shareholder proposals
Stockholders will vote on electing three Class II directors for three-year terms, ratifying Ernst & Young LLP as auditor, and an advisory say-on-pay vote for executive compensation.
The board recommends voting FOR all proposals.
Board of directors and corporate governance
The board consists of seven members, classified into three staggered terms; three Class II directors are up for election.
The board is majority independent, with robust governance guidelines, codes of conduct, and annual board evaluations.
The Executive Chairman leads the board during the CEO transition, with flexibility in leadership structure.
Committees include Audit, Compensation and Human Capital, Nominating and Governance, and Compliance and Quality, each with defined oversight roles.
Director compensation includes cash and equity, with annual RSU grants and committee chair retainers.
Latest events from agilon health
- Profitability surged in Q1 2026, prompting raised full-year guidance and strong liquidity.AGL
Q1 20267 May 2026 - Tim O'Rourke named CEO and Director with new compensation terms; no changes to voting matters.AGL
Proxy filing27 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.AGL
Proxy filing23 Apr 2026 - 2026 guidance targets breakeven EBITDA and $5.5B revenue after cost discipline and transformation.AGL
Q4 20257 Apr 2026 - Shareholders approved a reverse stock split and adjournment proposal, both backed by the Board.AGL
EGM 202617 Mar 2026 - Transformation, data-driven care, and disciplined contracting set the stage for growth and stability.AGL
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Disciplined contracting, cost controls, and clinical programs drive margin gains amid elevated trends.AGL
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Stockholders to vote on a reverse stock split, reducing shares to as low as 16.6 million.AGL
Proxy Filing20 Feb 2026 - Virtual vote on reverse stock split and adjournment proposal to maintain NYSE compliance.AGL
Proxy Filing18 Feb 2026